Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Below averageBioMarin Pharmaceutical Inc. (BioMarin, we, us or our) is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Our San Rafael, California-based company, founded in 1997, has a proven track record of innovation, with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, we seek to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Business segments
Jun 2026 · $989.7MThe company’s own SEC segment disclosure.
- VOXZOGO$252.5M26%
- VIMIZIM$194.4M20%
- NAGLAZYME$135.3M14%
- PALYNZIQ$135.2M14%
- GALAFOLD$105.7M11%
- BRINEURA$51.4M5%
- Other (5)$115.3M12%
BioMarin Pharmaceutical Inc. (BMRN) reported revenue of $766M in Q1 2026 (quarter ended Mar 31, 2026), up 2.8% from the same quarter a year earlier. That came with a gross margin of 75% and net income of $106M (14% of revenue). For the full year FY2025, revenue was $3.22B (+13% year on year) and net income $349M. Its largest product in Jun 2026 was VOXZOGO at $253M, 26% of the disclosed total, just ahead of VIMIZIM at 20%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.